RxDoctor Payments Data

Sheron Randolph, MD

Family Medicine · Indianapolis, INNPI 1922022235

Payments from drug & device makers

$2,076in general payments, 2019–2025

Across 112 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$488
  • AstraZeneca$171
  • Lilly USA, LLC$170
  • AbbVie$132
  • Pfizer$106
  • Boehringer Ingelheim$104
  • plus $905 from 25 others

What the payments were for

  • Food & beverage$2,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,076 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$22,741
Medicare patients
56
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide55$88,070
JanuviaSitagliptin Phosphate51$46,537
OzempicSemaglutide16$34,558
RybelsusSemaglutide11$27,212
JardianceEmpagliflozin25$20,349
MounjaroTirzepatide12$16,491
FarxigaDapagliflozin Propanediol15$16,265
Spiriva RespimatTiotropium Bromide17$11,785
Breo ElliptaFluticasone/Vilanterol15$10,900
SymbicortBudesonide/Formoterol Fumarate12$6,967
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,933
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,299
Atorvastatin Calcium320$2,368
Amlodipine Besylate309$1,255
Irbesartan49$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$170$104,56167 claims
Novo NordiskOzempic, Rybelsus$488$61,76927 claims
Boehringer IngelheimJardiance, Spiriva Respimat$104$32,13442 claims
AstraZenecaFarxiga, Symbicort$171$23,23227 claims
GSKBreo Ellipta, Shingrix$103$14,83233 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$960104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →